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Abstract
Background: Mucoepidermoid carcinoma (MEC) arises from multiple organs and accounts for the most common
types of salivary gland malignancies. Currently, patients with unresectable and metastatic MEC have poor long-term
clinical outcomes and no targeted therapies are available. The majority of MEC tumors contain a t(11;19) chromosomal
translocation that fuses two genes, CRTC1 and MAML2, to generate the chimeric protein CRTC1-MAML2. CRTC1-MAML2
displays transforming activity in vitro and is required for human MEC cell growth and survival, partially due to its ability
to constitutively activate CREB-mediated transcription. Consequently, CRTC1-MAML2 is implicated as a major etiologic
molecular event and a therapeutic target for MEC. However, the molecular mechanisms underlying CRTC1-MAML2
oncogenic action in MEC have not yet been systematically analyzed. Elucidation of the CRTC1-MAML2-regulated
transcriptional program and its underlying mechanisms will provide important insights into MEC pathogenesis
that are essential for the development of targeted therapeutics.
Methods: Transcriptional profiling was performed on human MEC cells with the depletion of endogenous
CRTC1-MAML2 fusion or its interacting partner CREB via shRNA-mediated gene knockdown. A subset of target
genes was validated via real-time RT-PCR assays. CRTC1-MAML2-perturbed molecular pathways in MEC were
identified through pathway analyses. Finally, comparative analysis of CRTC1-MAML2-regulated and CREB-regulated
transcriptional profiles was carried out to assess the contribution of CREB in mediating CRTC1-MAML2-induced
transcription.
Results: A total of 808 differentially expressed genes were identified in human MEC cells after CRTC1-MAML2
knockdown and a subset of known and novel fusion target genes was confirmed by real-time RT-PCR.
Pathway Analysis revealed that CRTC1-MAML2-regulated genes were associated with network functions that are
important for cell growth, proliferation, survival, migration, and metabolism. Comparison of CRTC1-MAML2-regulated
and CREB-regulated transcriptional profiles revealed common and distinct genes regulated by CRTC1-MAML2 and
CREB, respectively.
Conclusion: This study identified a specific CRTC1-MAML2-induced transcriptional program in human MEC cells and
demonstrated that CRTC1-MAML2 regulates gene expression in CREB-dependent and independent manners. Our data
provide the molecular basis underlying CRTC1-MAML2 oncogenic functions and lay a foundation for further functional
investigation of CRTC1-MAML2-induced signaling in MEC initiation and maintenance.
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Background
Mucoepidermoid carcinoma (MEC) is the most common
malignant form of salivary gland tumors. MEC also de-
velops in various sites such as lung, thyroid, breast, skin,
pancreas, esophagus, and cervix [1–3]. Patients with
unresectable and metastatic MEC have poor long-term
clinical outcomes, and no targeted therapy is currently
available. A majority of MEC cases are associated with a
specific chromosomal t(11;19)(q14-21;p12-13) transloca-
tion that joins exon 1 of the CRTC1 gene to exons 2–5
of the MAML2 gene, resulting in the expression of a
new CRTC1-MAML2 fusion gene [4–7]. CRTC1 belongs
to the three-member CRTC (CREB-regulated transcrip-
tion co-activator) family that co-activates CREB-
mediated transcription [8, 9]. CRTC co-activators have
critical roles in regulating metabolism, aging, memory,
and cancer [10–12]. MAML2 belongs to the three-
member MAML (mastermind-like) family that co-
activates Notch receptor-induced transcription. MAML
co-activators are critical in development and diseases
including cancer [13, 14]. In human MEC, the CRTC1-
MAML2 fusion protein consists of the 42-aa amino ter-
minal CREB binding domain (CBD) of CRTC1 and the
981-aa carboxyl terminal transcriptional activation do-
main (TAD) of MAML2 [15]. Current evidence impli-
cates CRTC1-MAML2 fusion as a major etiologic
molecular event and a therapeutic target in human
MEC. First, the CRTC1-MAML2 fusion induced colony
formation of cultured epithelial RK3E cells and the
resulting fusion-transformed RK3E cells were capable of
forming subcutaneous tumors in immune-compromised
mice [15–17], indicating a role of the CRTC1-MAML2
fusion in epithelial cell transformation. Second, deple-
tion of endogenous CRTC1-MAML2 fusion significantly
reduced MEC cell growth and survival in vitro and the
growth of human MEC xenografts in vivo [18], demon-
strating a critical role of the CRTC1-MAML2 fusion
oncogene in the maintenance of MEC cancerous pheno-
types. Therefore, these studies strongly suggest that
CRTC1-MAML2 has an essential role in MEC initiation
and maintenance.
The CRTC1-MAML2 fusion oncoprotein is a nuclear
protein and functions as a transcriptional co-activator
[15]. CRTC1-MAML2 fusion interacts with the tran-
scription factor CREB through the CRTC1 CBD domain
and activates CREB-mediated transcription through the
MAML2 TAD domain [16, 19], thereby constitutively
activating CREB-mediated transcription. Aberrant CREB
activity contributes at least partially to CRTC1-
MAML2’s transforming activity [16]. More recent
studies showed that CRTC1-MAML2 had CREB inde-
pendent activities through the interaction of other nu-
clear factors such as AP-1 [20] and MYC [21]. These
data support that CRTC1-MAML2 drives oncogenic
transformation by impinging on multiple gene regulatory
pathways.
However, the molecular mechanisms that account for
the CRTC1-MAML2 fusion oncogene in tumorigenesis
have not been characterized systematically. The CRTC1-
MAML2 fusion has transcriptional co-activation activity
and its functions are mediated in large part by changes
in gene expression. Therefore, in this study we per-
formed global gene expression profiling and examined
the transcriptional program induced by the CRTC1-
MAML2 fusion oncoprotein that contributes to MEC
development and maintenance. Specifically, we interro-
gated changes in gene expression patterns in MEC cells
caused by the knockdown of CRTC1-MAML2 fusion
expression. We also determined the extent of CRTC1-
MAML2/CREB interaction in target gene regulation
through comparative analysis of transcriptional profiles
of MEC cells with CREB knockdown or CRTC1-
MAML2 knockdown. Our study revealed target genes
and mechanisms of CRTC1-MAML2 that potentially
contribute to MEC pathogenesis.
Methods
Plasmids
The pSuperRetro-GFP/Neo vector-based shRNAs target-
ing the MAML2 TAD domain of CRTC1-MAML2
(shMAML2) or control shRNA targeting luciferase gene
(shLuc) were previously described [18]. The pLKO.1-
based lentiviral constructs targeting the MAML2 por-
tion of CRTC1-MAML2 (RHS4533-NM_032427) were
purchased from Open Biosystems. Two good
shMAML2 were identified: shM2-1 (TRCN0000118837)
targeting the 3’ UTR with target sequence 5’-
CCCTGTCTAAACTCCAGGATA-3’; and shM2-3
(TRCN0000118839) targeting the exon 5 of MAML2
5’-CCCAAAGCAATTGTTAGCAAA-3’. Two pLKO.1-
based shRNAs targeting the exon 1 of MAML2 were
generated with the following shRNA targeting se-
quences: 5’-GGACGATATGAACGAGGTA-3’ (shM2-B1)
and 5’-TCGTTCATATCGTCCTTCA-3’ (shM2-C1). The
pLKO.1-based lentiviral shRNA constructs targeting
CREB (RHS4533-NM_004379) were obtained from Open
Biosystems and two good shCREB includes shCREB-
B9 (TRCN0000011085) with a target sequence 5’-
AATCAGTTACACTATCCACTG-3’ and shCREB-G9
(TRCN0000007308) with a target sequence 5’-TAAC
TGTTAGATTTATCGAGC-3’. The pKLO.1-scramble
shRNA control vector (shCtl) was obtained from
Addgene.
Cell culture
HSY (fusion-negative cell), H3118 (fusion-positive MEC
of the parotid gland), H292 (fusion-positive MEC of the
lung), 293 T (human 293 cells expressing SV40 large T
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antigen), and 293FT (derived from human 293 T) were
cultured in Dulbecco's modified Eagle's medium
(DMEM; Sigma) supplemented with 10 % inactivated
fetal bovine serum (Atlanta Biologicals) and 1 % penicillin/
streptomycin (Mediatech). Cells were grown at 37 °C
under 5 % CO2.
Retroviral and lentiviral transduction
For retroviral production, 293 T cells were first plated at
3 × 106 cells in 10-cm culture dishes and transfected
next day with 8 μg of retroviral constructs and 2 μg of
each packaging plasmids pMD.MLV and pMD2-VSV-G.
For lentiviral production, 293FT cells were transfected
with lentiviral vectors with pSPAX2 and pMD2.G
packaging plasmids. Superfect transfection reagents
(QIAGEN) were used. Viruses were collected at 48 and
72 h post-transfection. Target cells were subsequently
infected with the viruses in fresh complete medium
containing 8 μg/ml polybrene (Sigma) for 6 to 8 h twice
on two consecutive dates. For cells infected with
pSuperRetro-GFP/Neo plasmids, GFP-positive cells were
FACS-sorted at 72 h after viral infection. For cells in-
fected with pLKO.1 shRNA viruses, cells were harvested
at 72 h after viral infection for analysis.
Microarray experiments
Total RNA was extracted using TRIzol reagent (Invitrogen)
and purified by RNeasy Mini kit (QIAGEN). The yield
and quality of RNA were assessed using spectropho-
tometry and the Agilent 2100 Bioanalyzer (Agilent
Technologies). Microarray experiments including cDNA
preparation, hybridization, scanning, and image analysis of
Affymetrix GeneChip HG-U133 plus 2.0 microarrays were
performed in the Microarray Core facility at Dana-Farber
Cancer institute according to the manufacturer’s protocol
(Affymetrix). Experiments were performed either in dupli-
cate or triplicate.
Microarray analysis
Statistical tests were carried out using R/BioConductor
software [22]. Data pre-processing and normalization
were performed using the affy package [23]. Raw data
were normalized using the Robust Multichip Analysis
(RMA) approach. The detection of a present or absent
call for a gene in a sample was determined using
the Affymetrix GCOS software. Probe-sets defined as
“absent” calls across all the samples were removed from
data analysis to reduce the false positives. To identify
differentially expressed genes, the linear modeling ap-
proach and empirical Bayes statistics as implemented in
the limma package [24] were employed. The p-values
were adjusted using the Benjamini and Hochberg
method [25]. Genes with an absolute fold change of > =2
and a p-value < 0.05 were considered as significantly
differentially expressed. Hierarchical clustering of the
differentially expressed gene list was computed on log-
transformed normalized data. The microarray data were
deposited in NCBI Gene Expression Omnibus (GEO
Series GSE59795).
Functional enrichment analysis
Differentially expressed genes were analyzed in the con-
text of biological functions, pathways, and diseases using
the Ingenuity Pathway Analysis software (IPA; Ingenuity
Systems Inc) [26]. The p-value was calculated using
Fisher’s exact test to determine a potential significant
association between differentially expressed genes and
specific functional categories. A p-value < 0.05 was
considered to be statistically significant. For upstream
regulator analysis, z-scores were calculated to predict
upstream regulators such as transcription factors, ki-
nases, compounds or drugs. The z-score is dependent
on gene expression in the input dataset and the know-
ledge of expected effects between regulators and their
known target genes in the Ingenuity Knowledge Base.
The statistically significant overlap between the dataset
genes and the known target genes was also calculated by
Fisher’s Exact test. An upstream regulator with a z-score
of >2 (or < −2) and p <0.01 was considered as signifi-
cantly “activated” or “inhibited”.
The fusion-regulated and CREB-regulated genes gen-
erated from our microarray data were also subjected for
Gene Set Enrichment Analysis (GSEA) analysis to iden-
tify potential functional enrichment. GSEA consists of
three major steps: calculation of an enrichment score
(ES), estimation of the significance level of the ES, and
adjustment for multiple hypothesis testing [27]. For this
study, the curated motif gene sets (C3:TFT, version 3.1)
in Broad Molecular Signature Database (MSigDB) [28]
were used to determine enriched transcription factors in
the fusion or CREB knockdown datasets. This motif
gene set included genes annotated as transcription factor
(TF) targets from TRANSFAC database. Genes were
ranked according to the correlation of gene expres-
sion with fusion or CREB knockdown using the
signal-to-noise ratio, and gene set permutations were
used for assessments of significance. Gene sets with FDR
p-value <0.25 were considered as significantly enriched.
Real-time RT-PCR
Real-time RT-PCR was performed as previously de-
scribed [18]. RNA was reverse transcribed into cDNA
using a GeneAmp RNA PCR kit (Applied Biosystems).
Real-time PCR was performed with the StepOne Real-
Time PCR System (Applied Biosystems) using the SYBR
Green PCR Core Reagents Kit (Applied Biosystems).
GAPDH was used as an internal control for the
normalization of gene expression. The primers used are
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as follows: CRTC1-MAML2 primers (Forward, 5’-TTC
GAGGAGGTCATGAAGGA-3’; Reverse, 5’-TTGCTG







primers (Forward, 5'- TGTCCTGGATGACGTGCGC
TG-3'’; reverse, 5'-GGTCGGCAACGTGTCTGAGCA-3');
STC1 primers (Forward, 5'-TGATCAGTGCTTCTG
CAACC-3'; Reverse, 5’-GTTGAGGCAACGAACCACTT-
3’); PDE4B primers (Forward, 5'-CCGATCGCATT
CAGGTCCTTCGC-3'; Reverse, 5’- TGCGGTCTGT
CCATTGCCGA-3’); RUNX3 primers (Forward, 5'- CA
GAAGCTGGAGGACCAGAC-3'; Reverse, 5’-TCGGA
GAATGGGTTCAGTTC-3’); PTGS1 primers (Forward,
5’-GCTCTGGTTCTTGCTGTTCC-3’; Reverse, 5’-TGG
TGCTGGCATGGATAGTA-3’); TGFB2 primers (Forward,





CAATG-3'; Reverse, 5’- AGCGAGCCGATCCCTCC
TCT-3’); and GAPDH primers (Forward, 5’-CAATG
ACCCCTTCATTGACC-3’; Reverse, 5’-GACAAGCTT
CCCGTTCTCAG-3’). Significant differences between
two groups were analyzed using Student’s t-test. A p-
value < 0.05 was considered statistically significant.
Western blotting
Cellular protein extracts were prepared as previously
described [18]. For immunoblot analysis, protein extracts
were fractionated in SDS-polyacrylamide gels and then
electro-transferred to nitrocellulose membranes. The
membranes were blocked for 1 h in a buffer containing
10 mM Tris, pH 8.0, 150 mM NaCl, 0.05 % Tween 20,
and 5 % nonfat dry milk. The membranes were then
incubated with the antibodies (anti-MAML2 TAD,
Cell signaling CST-4618; or anti-β-actin, Santa Cruz
sc-47778) overnight at 4 °C, washed, and then incubated
with a horseradish peroxidase-conjugated secondary anti-
body for 1 h at RT. The protein bands were detected using
enhanced chemiluminescence (Pierce).
Results
Microarray analysis identified downstream target genes
specifically regulated by the CRTC1-MAML2 fusion
oncoprotein
The CRTC1-MAML2 fusion oncogene was implicated
in tumor initiation and maintenance of human MEC
[16–18]. Previously, a number of target genes were
found differentially expressed in cervical cancer Hela
cells after CRTC1-MAML2 was over-expressed [16, 19],
which uncovered an important activity of CRTC1-
MAML2 in constitutive activation of CREB-mediated
gene expression. However, the relevant physiological tar-
gets of the CRTC1-MAML2 fusion oncoprotein in human
MEC cells remained to be systematically identified. The
identification of the fusion target genes and pathways will
be important to explain specific and frequent association
of CRTC1-MAML2 and MEC. We hypothesized that
CRTC1-MAML2 fusion oncogene induced a specific
transcriptional program that contributes to MEC initiation
and maintenance. To identify the CRTC1-MAML2-
induced transcriptional program, we examined the effect
of CRTC1-MAML2 depletion on gene expression profile
changes in human fusion-positive MEC cells by micro-
array analysis.
The CRTC1-MAML2 fusion gene consists of exon 1 of
the CRTC1 gene fused to exons 2–5 of the MAML2
gene (Fig. 1a). Ideally, shRNA that specifically targets
the fusion junction should be used to investigate the
specific effect of loss-of-function of CRTC1-MAML2.
However, we failed to obtain any shRNA that could
cause specific, effective knockdown of CRTC1-MAML2
expression. Therefore, we took an approach that allowed
us to investigate CRTC1-MAML2-regulated genes in hu-
man MEC cells (Fig. 1b). We utilized pSuperRetro-based
retroviruses co-expressing shRNA targeting MAML2-
TAD region (shMAML2) and GFP from a bicistronic
transcript. shMAML2 led to MAML2 knockdown in
fusion-negative HSY cells and knockdown of both
MAML2 and CRTC1-MAML2 in fusion-positive H3118
cells [18]. The pSuperRetro-based shRNA retroviruses
co-expressing luciferase shRNA (shLuc) and GFP were
used as controls. Here, we first performed retroviral in-
fection of fusion-negative HSY cells and fusion-positive
H3118 cells using control shLuc or shMAML2 retrovi-
ruses in duplicate. At 72 h after infection, transduced
cells were FACS-sorted for GFP expression to enrich cell
populations containing shRNAs, as shRNAs were co-
expressed with GFP in the transduced cells. The sorted
GFP-expressing cells were processed for the isolation of
RNA. Subsequently, gene expression profiling was per-
formed using Affymetrix human genome U133 plus
2.0 arrays that covered approximately 38,500 well-
characterized human genes.
We adopted a criteria with an absolute fold-
change > = 2.0 and a p-value < 0.05 to define the differ-
entially regulated genes. The number of differentially
expressed genes and overall gene expression patterns
were shown in Venn diagram, heatmap (Fig. 1c-d) and
volcano plots (Additional file 1: Figure S1). Differen-
tially expressed genes in fusion-negative cells after the
transduction of shMAML2 viruses in comparison with
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shLuc control represented MAML2-regulated gene
candidates (Fig. 1b), which contained 13 up-regulated
and 49 down-regulated genes (Fig. 1c). On the other hand,
differentially expressed genes between shMAML2-
expressing and shLuc-expressing fusion-positive cells rep-
resented fusion/MAML2-regulated genes (Fig. 1b), which
consisted of a total of 432 up-regulated and 378 down-
regulated genes (Fig. 1c). To determine genes that were
specifically regulated by CRTC1-MAML2 fusion, we fil-
tered out 2 genes from fusion/MAML2-regulated gene list
that showed the same regulated direction as in MAML2-
regulated genes (Fig. 1b-c, Additional file 2: Table S1).
Finally, our analysis identified a total of 808 differentially
expressed genes after CRTC1-MAML2 knockdown in
human fusion-positive MEC H3118 cells, including 376
down-regulated genes and 432 up-regulated genes
(Additional file 2: Table S1).
Validation of the CRTC1-MAML2 target genes from
microarray analysis
The CRTC1-MAML2 fusion oncoprotein is a transcrip-
tional co-activator [15, 16], so we next focused on genes
whose transcription was down regulated in response to
CRTC1-MAML2 knockdown in human MEC cells for
Fig. 1 Transcriptional profiling analysis revealed target gene candidates regulated by the CRTC1-MAML2 fusion oncogene in human MEC cells.
a The t(11;19) translocation fuses exon 1 of the CRTC1 gene to exons 2–5 of the MAML2 gene and generates the CRTC1-MAML2 fusion consisting
of CRTC1 CREB binding domain (CBD) and MAML2 transcriptional activation domain (TAD). b The strategy in identifying CRTC1-MAML2-regulated
genes by microarray analysis was shown. Fusion-negative cells (HSY) and fusion-positive cells (H3118) were infected with retroviral-mediated
MAML2 shRNA-IRES-GFP (co-expressing MAML2 shRNA and GFP) or luc shRNA-IRES-GFP (co-expressing luciferase shRNA and GFP that serves as a
control) for 72 h. GFP-positive cells were then FACS-sorted, and RNA samples were collected for microarray analysis using HG-U133 Plus 2.0 arrays.
Comparison of MAML2-knockdown HSY cells and the control cells resulted in MAML2-regulated gene candidates (list A), while comparison of
fusion/MAML2-knockdown H3118 cells and the controls led to fusion/MAML2-regulated genes (list B). Based on these two lists of target genes,
fusion-regulated genes were identified by filtering out the list A from the list B (List: B-A). c, d Venn diagram (c) and heatmap (d) show differentially
expressed genes in both fusion-negative HSY and fusion-positive cells after shMAML2 transduction. Two biological replicates were analyzed. This
analysis led to the identification of a total of 808 fusion-regulated candidate genes, with 376 down-regulated and 432 up-regulated genes
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the validation of the microarray results. From the
CRTC1-MAML2 regulated gene list (Additional file 2:
Table S1), we have selected several genes that were
known to be critical players in tumor development
and progression, or therapeutic targets with clinical or
preclinical inhibitors available, or potential diagnostic
or prognosis markers (Table 1). A total of 10 CRTC1-
MAML2-regulated target gene candidates were tested in
human MEC by RT-qPCR, including a recently identi-
fied target AREG [16] and 9 novel targets including
LINC00473, DMBT1, STC1, PDE4B, RUNX3, PTGS1,
TGFB2, ODC1, and CDK6. Specifically, we used an in-
dependent set of lentiviral-based shRNAs, including 2
shRNAs targeting respective sequences in the exon 5
and 3’ UTR of the MAML2 gene (shM2-3, shM2-1) and
2 shRNAs targeting the exon 1 of MAML2 (shM2-B1,
shM2-C1) (Fig. 2a). Scramble shRNA was used as a
control (shCtl). Fusion-positive H3118 MEC cells were
infected twice with these lentiviruses on two consecutive
days. RNA and protein samples were then isolated at
72 h after the first infection. As expected, both shM2-3
and shM2-1 lentiviruses caused knockdown of MAML2
and CRTC1-MAML2 fusion in fusion-positive MEC
cells, while shM2-B1 and shM2-C1 led to only MAML2
knockdown at both the transcript and protein levels
(Fig. 2c-d). We found that knockdown of both CRTC1-
MAML2 and MAML2 via shM2-1 or shM2-3 caused
down-regulation of the known AREG gene as well as 9
novel targets including LINC00473, DMBT1, STC1,
PDE4B, RUNX3, PTGS1, TGFB2, ODC1, and CDK6 in
fusion-positive MEC H3118 cells (Fig. 2c). However,
expression levels of these genes were not significantly
Table 1 A subset of CRTC1-MAML2 target gene candidates is shown








LINC00473a long Intergenlc non-protein
coding RNA 473
−37.12 −1.03 Unknown other
Plasma transmembrane
DMBT1a deleted in malignant brain
tumors 1
−35.73 1.16 Membrane receptor
secreted
STC1a stanniocalcin 1 −21.74 1.03 Extracellular glycoprotein Diagnosis
PDE4B phosphodiesterase 4B,
cAMP-specific
























ODC1 ornithine decarboxylase 1 −2.54 −1.06 Cytoplasm enzyme Eflornithine Efficacy
AP-12009
TGFB2a transforming growth factor,
beta 2
−2.48 1.21 Extracellular growth factor Lerdelimumab Efficacy
Diagnosis
AREGa Amphiregulin −2.23 1.11 Extracellular growth factor Cetuximab, gefitinib Efficacy
Prognosis





CDK6 cvclin-deDendent kinase 6 −2.07 1.02 Nucleus kinase PD-0332991 Proanosis
flavopiridol
The fold changes of gene expression were shown for fusion-positive MEC H3118 cells with fusion/MAML2 knockdown (KD), and fusion-negative HSY cells with
MAML2 KD
a Genes down-regulated in H3118 cells with CREB KD
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affected when only MAML2 was knocked down using
shRNAs that target the exon 1 of the MAML2 gene
(shM2-B1 and shM2-C1) (Fig. 2d). Therefore, our data
indicate that expression of these 10 target genes was reg-
ulated by the CRTC1-MAML2 fusion in human MEC
H3118 cells, which was consistent with the gene expres-
sion changes shown by our microarray data. Moreover,
using similar strategies, we subsequently performed gene
validation in a second MEC cell line, a human lung
MEC H292 cell line. We found that 6 out of these 10
genes were regulated by CRTC1-MAML2, while 4 of
them including RUNX3, PTGS1, TGFB2 and CDK6 were
not (Additional file 1: Figure S2). These data suggest that
CRTC1-MAML2 regulates common target genes as well
as specific cell context dependent targets in different
MEC cells.
Pathway analysis of CRTC1-MAML2-regulated genes
revealed a role of CRTC1-MAML2 in regulating multiple
signaling pathways that are important in tumorigenesis
To examine CRTC1-MAML2-regulated genes from
the microarray data in a biologically relevant manner,
we next performed functional enrichment analysis.
Here, the CRTC1-MAML2 fusion-regulated gene set
(Additional file 2: Table S1) was subjected to Ingenuity
Pathway Analysis (IPA) in identifying over-represented
biological functions and pathways. The top 20 enriched
molecular and cellular functions in the CRTC1-MAML-
regulated genes were shown in Fig. 3a, revealing that
CRTC1-MAML2 fusion had associated functions in cellu-
lar processes such as cellular movement, development,
death and survival, growth and proliferation, cell-to-
cell signaling and interaction, and metabolism. The
Fig. 2 Real-time RT-PCR assays validated a subset of CRTC1-MAML2 fusion-regulated genes identified from microarray analysis. a Lentiviral
pLKO.1-based shRNAs targeting various regions of the MAML2 gene were indicated. These shRNAs and scramble control shRNA (shCtl) lentiviruses
were used to infect the CRTC1-MAML2 fusion-expressing H3118 MEC cells and the infected cells were processed to isolate protein lysates for
Western blotting analysis and RNA for real-time RT-PCR assays. b Western blot analysis showed shM2-1 or shM2-3 led to the knockdown of
MAML2 and fusion, whereas that shM2-B1 or shM2-C1 caused MAML2 knockdown only. It is noted that another shRNA, shM2-A1 targeting the
exon 1 of MAML2 did not cause MAML2 knockdown. c, d Real-time RT-PCR analyses showed that knockdown of both CRTC1-MAML2 fusion and
MAML2 in H3118 MEC cells led to reduced transcripts levels of a known target AREG and a subset of novel fusion target genes, including
LINC00473, DMBT1, STC1, PDE4B, RUNX1, PTGS1, TGFB2, ODC1, and CDK6 (c), whereas MAML2 knockdown in H3118 MEC cells did not significantly
affect their expression (d). The level of CRTC1-MAML2 fusion transcript was determined using a primer set that spans the chromosomal translocation
breakpoint. The level of MAML2 knockdown was determined using the primers that amplify the exon 1 of MAML2. Data are presented as mean ± S.E.
(n = 3, *p < 0.05)
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top over-represented canonical signaling pathways in-
cluded modulation in commonly observed “Cancer”
signatures, such as the regulation of matrix metallo-
proteases, cancer metastasis signaling, HIF1α signaling,
and HER-2 signaling (Fig. 3b).
IPA upstream regulator analysis allows the identifi-
cation of the “activation or inhibition state” of specific
upstream regulators in a gene set. CRTC1-MAML2
fusion is a transcriptional co-activator, so we focused on
those genes that were activated by CRTC1-MAML2.
Fig. 3 Pathway analysis revealed that CRTC1-MAML2 fusion induces critical cancer cell signaling. a Functional classification of fusion-regulated
genes (Additional file 2: Table S1) was performed using Ingenuity Pathway Analysis (IPA). The top 20 Molecular and Cellular Functions were ranked
based on p-value, and the bars represent inverse log of the p-value (x-axis). b Top 20 Canonical Signaling Pathways that were enriched
in fusion-regulated genes were shown. These pathways were ranked based on p-value, and the bars represent inverse log of the p-value
(x-axis). c Upstream regulators analysis identified several transcription regulators regulated CRTC1-MAML2 fusion targeted genes. Changes
in the activation status of transcription regulators were plotted based on their activation z-score from IPA. Positive z-score indicates activation and
negative z-score indicates inhibition. d Upstream regulators analysis identified several drugs or kinase inhibitors regulated CRTC1-MAML2
fusion targeted gene expression. e MAPK inhibitor (U0126) regulated several CRTC1-MAML2 fusion down-regulated genes (Activation z-score:
3.89; p-value of overlap: 1.65E-5), suggesting that fusion function can be blocked by the inhibition of the MAPK pathway
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Therefore, we used the fusion depletion-induced down-
regulated gene set in Additional file 2: Table S1, and pre-
dicted the altered states of transcription regulator families.
Using a criteria with a z-score of > 2.0 or < −2.0 and a
p-value < 0.01, our analysis predicted the inhibition of
several transcription regulators in fusion-knockdown
gene set including known CRTC1-MAML2 interactors
such as CREB, EP300, CREBBP, and MYC [16, 21],
and transcription regulators that were not previously
linked with CRTC1-MAML2 such as NF-κB complex,
TP53, E2F1, HIF1A, ATF2, GLI1, NF-AT, TP63, KLF4,
IRF6, STAT6, and FOXL2 (Fig. 3c). These data strongly
suggest that CRTC1-MAML2 interacts functionally with
multiple signaling pathways associated with these regula-
tors, which could contribute to CRTC1-MAML2 fusion
oncogenic functions. It should be noted that JUN was also
identified outside a cutoff score but with a z-score of −1.7,
supporting a reported interaction of CRTC1-MAML1 and
AP-1 (FOS/JUN) [20].
Moreover, this analysis predicted that biologic drugs
such as cyclosporine A (an immunosuppressant) and
infliximab (a monoclonal antibody against TNF-α), and
small-molecule kinase inhibitors such as MAPK inhibi-
tors (PD98059 and U0216), PI-3 K inhibitor (LY294002),
p38 MAPK inhibitors (SB203580 and SB202190), PKA
inhibitor (H89), PKC inhibitors (Ro31-8220, BMI1, and
Go6976), JNK inhibitor (SP600125), and tyrosine kinase
inhibitor for JAK2 and EGFR (AG490), affected gene ex-
pression in the same direction as the knockdown of
CRTC1-MAML2 fusion (Fig. 3d). For instance, the
MAPK inhibitor U0126 was identified to cause down-
regulation of multiple fusion target genes (Fig. 3e), an ef-
fect similar to CRTC1-MAML2 knockdown. Therefore,
our data strongly suggest that these biologic drugs and
small molecule inhibitors might be effective in inhibiting
CRTC1-MAML2 fusion functional activity and blocking
MEC growth.
Identification of CREB-dependent CRTC1-MAML2-regulated
genes
We previously showed that the CRTC1-MAML2 fu-
sion interacts with the transcription factor CREB
through the CRTC1 CREB binding domain (CBD),
and constitutively activates CREB-mediated transcrip-
tion via the MAML2 transcription activation domain
(TAD) [16]. Moreover, CRTC1-MAML2 was able to
interact with AP1 [20] and MYC [21]. To determine
the extent to which CRTC1-MAML2 induces the spe-
cific transcriptional program in human MEC cells
through the CREB transcription factor, we evaluated
the contribution of CREB in CRTC1-MAML2 regula-
tion of target gene expression.
We hypothesized that genes controlled by functional
interaction of CRTC1-MAML2 fusion and CREB would
be down regulated in response to either CRTC1-
MAML2 or CREB depletion. Therefore, we determined
target genes specifically regulated by CREB in fusion-
positive MEC by comparing the impact of CREB knock-
down on the gene expression patterns of fusion-positive
H3118 MEC cells as well as fusion-negative HSY cells.
Here, lentiviruses expressing CREB shRNA (shCREB)
and scramble shRNA control (shCtl) were used to infect
fusion-negative HSY cells and fusion-positive H3118
cells. RNA samples were prepared from 3 biological
replicates at 72 h after viral infection. Gene expression
profiling analyses were performed with Affymetrix
GeneChip HG-U133 plus 2.0 arrays. Using an absolute
fold change of gene expression of > = 2.0 and a p value
of < 0.05 as a cutoff, we identified 298 down-regulated
and 130 up-regulated genes in fusion-negative HSY cells
and 1531 down-regulated and 368 up-regulated genes in
fusion-positive H3118 cells after CREB depletion (Fig. 4a,
Additional file 1: Figure S3). Comparison of CREB-
regulated targets in HSY and H3118 cells showed com-
mon and distinct CREB targets in both cell lines. The list
of differentially regulated genes affected by CREB knock-
down in fusion-positive H3118 cells but not in fusion-
negative cells was shown in Additional file 2: Table S2.
The heatmap and volcano plots showing changes in both
HSY and H3118 cells before and after CREB knockdown
were shown in Fig. 4b and Additional file 1: Figure S3.
We next compared CRTC1-MAML2-regulated and
CREB-regulated gene lists in H3118 cells, and found a
significant overlapping group of genes in fusion-positive
MEC H3118 cells with 127 down-regulated and 29 up-
regulated genes (Fig. 4c; Additional file 2: Table S3),
which suggested the co-regulation of these genes by
CRTC1-MAML2 and CREB interaction. To determine
whether they were potential direct CREB targets, we
compared this group of CRTC1-MAML2/CREB target
genes with a dataset that collected a total of 15,784
RefSeq genes with predicted CREs (cAMP-responsive
elements; CREB binding site) and 3,666 of them with
conserved full and half CREB sites within −3 kb to
300 bp from TSS [29]. We found that 55.8 % of these
genes contain the predicted CRE binding sites and
34.5 % of them contain conserved CRE sites (Fig. 4d),
supporting that they are potential direct CREB targets.
These data strongly support that a major action of
CRTC1-MAML2 in activating gene expression is through
CREB.
Gene set enrichment analysis (GSEA) analyses further
demonstrate the interaction of CRTC1-MAML2 fusion and
CREB in human MEC cells
To further evaluate our hypothesis that a significant set
of genes are regulated by the CRTC1-MAML2/CREB
interaction, we performed GSEA to determine any
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correlation of CRTC1-MAML2-regulated or CREB-
regulated genes in H3118 cells. GSEA is computational
approach that evaluates the distribution of genes in
the pre-defined gene sets in the fold change ordered
list. The enrichment score (ES) and the weighted
Kolmogorov-Smirnov-like statistics indicate whether
genes in the pre-defined gene sets are randomly distrib-
uted or statistically significantly correlated with pheno-
typic states (i.e. knockdown vs. control). We first analyzed
the C3 TF motif gene set collection from the MsigDB
(version 3.1) that contains gene sets annotated as tran-
scription factor targets using the TRANFAC database. We
found that CREB-related transcription binding motifs
dominated the top 20 transcription factor target gene sets
which were enriched in down-regulated genes in fusion-
knockdown H3118 cells (Fig. 4e). This data further
suggest a major mode of action of CRTC1-MAML2
in transcriptional activation is mediated by CREB. We
then used up- or down-regulated genes in fusion
knockdown cells (Additional file 2: Table S1) and up-
or down-regulated genes in CREB knockdown cells
(Additional file 2: Table S2) as pre-defined gene sets
for GSEA analysis. We observed concordant enrichment
between fusion knockdown-induced down-regulated
genes and CREB knockdown-induced down-regulated
genes (Fig. 4f, g). Therefore, genes down-regulated
after CREB depletion is generally down regulated after
fusion depletion, and vice versa, strongly supporting
that the CRTC1-MAML2 fusion interacts with CREB
to positively regulate a significant percentage of its
direct target genes in MEC. It should be noted that
there was another significant portion of fusion target
genes that were not overlapping with CREB target
genes, suggesting that CRTC1-MAML2 also acts
through other CREB-independent transcription factors
in mediating its oncogenic functions.
Fig. 4 Transcriptional profiling analysis revealed a major action of CRTC1-MAML2 fusion in co-activating CREB target genes in human MEC cells.
a Venn Diagram indicated that CREB knockdown in fusion-negative HSY and fusion-positive H3118 cells caused gene expression changes in
distinct and common genes. Down-regulated and up-regulated genes were shown in green and red. b A heatmap of differential expressed
genes in HSY and H3118 cells after shCREB transduction. Three biological replicates for each group were included in the analysis. c Venn
Diagram indicated distinct and overlapping genes between fusion knockdown and CREB knockdown in H3118 cells. d A significant subset
of CRTC1-MAML2 and CREB common-regulated genes showed CREB binding sites on their promoters. Comparison of the fusion/CREB-regulated
genes and the gene set with CREB binding site in the promoter revealed 55.8 % of the fusion/CREB target genes contain CREB binding site.
e Top 20 transcription factors whose target gene sets were enriched in down-regulated fusion knockdown H3118 array. Each gene set contains
genes that shared a transcription factor-binding site defined in the TRANSFAC (version 7.4) database. “Size” represents the number of genes in
each data set, “NES” the normalized enrichment score calculated by the GSEA, and the “FDR q-val” is error adjusted false discover rate. CREB-related
transcription binding motifs were dominated. f GSEA plot indicates that genes down-regulated by fusion knockdown were over-represented at the
right of the entire ranked list, which represent the down-regulated genes caused by CREB knockdown (NES −2.548 and FDR q-value < 0.0001). The
solid bars represent each individual gene in fusion down-regulated gene set. g GSEA plot indicates that CREB down-regulated genes were
over-represented at the right (down-regulated by Fusion KD) of the entire ranked list (NES −2.307 and FDR q-value < 0.0001). The solid bars
represent each individual gene in fusion down-regulated gene set
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Discussion
Currently diagnostic markers and new effective thera-
peutic targets for human MEC tumors remain to be
identified. The CRTC1-MAML2 fusion gene is highly
associated with human MEC and is implicated in MEC
tumorigenesis and maintenance. Therefore, clinical im-
provements for patients with MEC would require a bet-
ter understanding of CRTC1-MAML2 regarding its
altered signaling and molecular actions. In this study, we
identified CRTC1-MAML2-regulated transcriptional pro-
gram in human MEC cells through expressional profiling.
Our data suggest that CRTC1-MAML2 mediates its onco-
genic functions in CREB-dependent and –independent
manners.
To identify CRTC1-MAML2-induced transcriptional
profiles, we initially took a subtractive approach that
compared gene expression profiles of fusion–positive
H3118 cells depleted with both CRTC1-MAML2 fusion
and MAML2 and of fusion-negative HSY cells depleted
with MAML2 only (Fig. 1b). It should be noted that
there were limitations with this approach, as MAML2-
regulated target genes in MEC H3118 cells might be dif-
ferent from those in HSY cells. The optimal approach
will be to profile and compare the same MEC cells that
are depleted of both the CRTC1-MAML2 fusion and
MAML2, and MAML2 only. Therefore, the list of
CRTC1-MAML2-regulated target candidates should be
further validated in the future to ensure that they are
indeed targets for CRTC1-MAML2, but not MAML2.
However, we think our approach is valuable in providing
a list of relevant target genes for further analysis. First,
MAML2 expression is very low as compared to the
CRTC1-MAML2 fusion in human MEC cells (Fig. 2b).
Therefore, MAML2 depletion might not cause profound
expression changes and cellular functions. Consistent
with this, MAML2 depletion alone did not significantly
affect cell proliferation and survival in human MEC cells
[18]. Also, there were fewer MAML2 regulated target
genes (Fig. 1c) and only two MAML2-regulated genes
were found in the fusion/MAML2 gene list (Fig. 1c).
Second, when we performed gene validation, we were
able to obtain shRNA lentiviruses that specifically tar-
geted both fusion and MAML2, or MAML2 only in the
same fusion-positive MEC cells (Fig. 2). We validated all
of the 10 target genes in MEC H3118 cells, which is
consistent with the microarray data from H3118 cells.
Therefore, we think the approach we took is feasible to
identify relevant fusion target genes in H3118 cells.
Using a similar validation strategy through gene expres-
sion analysis of isogenic cells, we confirmed 6 out of
these 10 CRTC1-MAML2 regulated genes in a second
MEC cell line, human lung MEC H292. These data sug-
gest that there is a common CRTC1-MAML2-regulated
transcriptional program in various MEC cancer cells.
However, MEC tumors arising from different organs
might have different target genes beside the common
core transcriptional targets due to the potential inter-
action of CRTC1-MAML2 fusion with cell type-specific
factors, and subsequently could manifest different
biological behaviors. Therefore, the CRTC1-MAML2
fusion-regulated transcriptional program in human MEC
H3118 that we identified will serve as a foundation for
future in-depth analyses of bona-fide genes and path-
ways regulated by CRTC1-MAML2 fusion. Currently
fusion-associated gene signatures have not been evalu-
ated in human MEC tumors. Our fusion-regulated target
candidates in H3118 cells will provide important infor-
mation for the identification of gene signatures associ-
ated with fusion-positive tumors, which will be useful
for accurate diagnosis of tumors with CRTC1-MAML2
activity as well as evaluation and assignment of specific
therapeutic intervention.
To gain biological insights into the CRTC1-MAML2
oncogenic activity, we subsequently performed canonical
pathway enrichment analysis and the derivation of mech-
anistic networks using The Ingenuity Pathways Analysis
(IPA) tool. The data strongly suggest that CRTC1-
MAML2 fusion have critical functions associated with cell
proliferation, growth, survival, movement, metabolism
and cell signaling, which can be further investigated.
Moreover, IPA upstream regulator analysis identified small
molecule inhibitors and biologic drugs that were predicted
to cause gene signature changes that were similar to
CRTC1-MAML2 fusion gene knockdown, suggesting that
those small molecular inhibitors or biologic drugs likely
block the fusion oncogenic functions. We found that the
MAPK inhibitor U0126, similar to CRTC1-MAML2
knockdown, caused down-regulation of multiple fusion
target genes (Fig. 3e). This data is consistent with our re-
cent study demonstrating that CRTC1-MAML2 fusion in-
duced expression of an EGFR ligand AREG, which acted
in an autocrine fashion and bound to functional EGFR on
human MEC cells to initiate EGFR signaling and activate
MAPK signaling. Activated MAPK signaling was demon-
strated in human MEC cells by Western blotting analysis
for p-Erk in human MEC xenografts, and primary human
MEC tumors [18, 30]. The blockade of this pathway via
EGFR blocking antibodies inhibited MAPK signaling and
inhibited MEC growth [18]. Therefore, MAPK inhibitors
could block fusion-induced MAPK signaling and might be
an effective way to block MEC tumors. Future studies in-
clude determining whether blockade of the critical down-
stream pathways, individually or in combination, with the
predicted drugs or biologics will affect MEC tumor
growth. These studies will help to identify effective ap-
proaches to treat MEC.
Mechanistically, how the CRTC1-MAML2 fusion
oncoprotein induces its transcriptional program is not
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fully understood. Previous evidence supports a model
that the CRTC1 CBD of CRTC1-MAML2 fusion inter-
acts with the transcription factor CREB and its MAML2
TAD co-activates CREB-mediated transcription [8, 16].
CREB activity was required for the transformation of the
CRTC1-MAML2 fusion in vitro and MEC cell growth,
strongly indicating an important role for CREB in
mediating CRTC1-MAML2 oncogenic functions. In this
study, we further evaluated the contribution of CREB
transcription factor in mediating CRTC1-MAML2 tran-
scriptional response in human MEC H3118 cells, and
identified a significant overlap between CRTC1-MAML2
and CREB target genes. These data support that
CRTC1-MAML2 co-activation of CREB-mediated tran-
scription is a major mechanism for CRTC1-MAML2
oncogenic function. We also found that more than half
of these genes contain predicted CRE binding sites.
Whether these genes are indeed directly regulated by
CRTC1-MAML2 and CREB interaction remain to be
addressed. One approach would be sequential chromatin
immunoprecipitation for CRTC1-MAML2 and CREB
followed by sequencing analysis.
We also identified CRTC1-MAML2 fusion target can-
didates that appear not to be regulated by CREB,
strongly suggesting that CRTC1-MAML2 also induces
its transcriptional program in a CREB-independent man-
ner. CRTC1-MAML2 was previously found to display
CREB-independent activities via interacting and co-
activating AP-1 [20] and MYC [21], both important for
CRTC1-MAML2 fusion transformation. Our analysis of
the fusion-regulated transcriptional program supports
the reported interactions of CRTC1-MAML2 fusion with
MYC and AP-1 but also suggest that fusion interacts
with other transcription regulators such as NF-κB com-
plex, TP53, E2F1, HIF1A, ATF2, GLI1, NF-AT, TP63,
KLF4, IRF6, STAT6, and FOXL2. Therefore, our analyses
suggest novel mechanisms of action of CRTC1-MAML2
fusion to interact with transcription factors besides CREB
in mediating its oncogenic functions. Future proteomic
analysis of endogenous CRTC1-MAML2 fusion protein
complexes and functional characterization of the protein
complex components in human MEC cancer cells will
provide insights into the mechanism of CRTC1-MAML2
fusion oncoprotein and reveal the novel regulators.
Conclusions
This study is the first to identify specific transcriptional
program associated with CRTC1-MAML2, a major
oncogene driver in human MEC. Our data provided
critical downstream cellular factors/pathways and poten-
tial molecular mechanisms of the CRTC1-MAML2
oncoprotein. This study will provide important informa-
tion for accurate diagnosis for fusion-positive MEC and
effective targeted therapeutic treatment.
Additional files
Additional file 1: Figure S1. Volcano plots showed differential
expression between MAML2 TAD shRNA and control groups in
fusion-negative HSY cells (A) and in fusion-positive H3118 cells (B).
The vertical lines corresponded to 2.0-fold up and down, respectively,
and the horizontal line represented a p-value of 0.05. NC denoted no
change. “Down” or “Up” referred to significantly down-regulated or
upregulated genes. Several fusion-regulated genes in H3118 cells
were indicated. Figure S2. Validation of a subset of CRTC1-MAML2
fusion-regulated genes in human MEC H292 cell line. Real-time RT-PCR
assays were performed in H292 cells that were depleted of fusion/
MAML2 or MAML2 only for a subset of CRTC1-MAML2 fusion candidate
genes identified in human MEC H3118 cells. Figure S3. Volcano plots
showed differential expression between CREB shRNA and control groups
in fusion-negative HSY cells (A) and in fusion-positive H3118 cells (B).
The vertical lines corresponded to 2.0-fold up and down, respectively,
and the horizontal line represented a p-value of 0.05. NC denoted no
change. “Down” or “Up” referred to significantly down-regulated or
up-regulated genes. (PDF 4339 kb)
Additional file 2: Table S1. A list of CRTC1-MAML2 fusion-regulated
genes in fusion-positive H3118 MEC cells. Gene expression profiling
analyses were performed on fusion/MAML2-knockdown H3118 cells
and MAML2-knockdown HSY cells in comparison with their corresponding
control cells. Differentially expressed genes with absolute fold change > = 2
and p < 0.05 were identified. The differentially expressed genes in fusion/
MAML2 knockdown H3118 cells showing the same regulated direction in
MAML2 knockdown HSY cells were filtered out. The “positive” and
“negative” signs denote upregulated or down-regulated genes in KD
compared to control groups, respectively. The asterisk indicates the
common gene in different regulatory direction between HSY and
H3118. Table S2. A list of differentially regulated genes affected by
CREB depletion in human fusion-positive MEC, but not fusion-negative cells.
The differentially expressed genes after CREB was depleted were identified
in both fusion-positive MEC H3118 cells and fusion-negative HSY cells.
Those CREB-regulated genes in H3118 cells showing the same regulated
direction in fusion-negative HSY were then filtered out. The “positive” and
“negative” signs denote up-regulated or down-regulated genes in KD
compared to control groups, respectively. The asterisk indicates the
common gene in different regulatory direction between HSY and
H3118 cells. Table S3. A list of common differentially expressed
genes affected by CRTC1-MAML2- or CREB-depletion in human MEC
H3118 cells. This gene list represents candidate genes regulated by
fusion/CREB interaction. The “positive” and “negative” signs denote
up-regulated or down-regulated genes in KD compared to control
groups, respectively. The asterisk indicates the common gene in different
regulatory direction between fusion and CREB. (PDF 707 kb)
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